1. Home
  2. HUDI vs XCUR Comparison

HUDI vs XCUR Comparison

Compare HUDI & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huadi International Group Co. Ltd.

HUDI

Huadi International Group Co. Ltd.

HOLD

Current Price

$0.95

Market Cap

11.5M

Sector

Industrials

ML Signal

HOLD

XCUR

Exicure Inc.

HOLD

Current Price

$1.15

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUDI
XCUR
Founded
1998
2011
Country
China
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
13.7M
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
HUDI
XCUR
Price
$0.95
$1.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
836.2K
40.9K
Earning Date
01-30-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
83.37
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$1.05
52 Week High
$5.46
$9.48

Technical Indicators

Market Signals
Indicator
HUDI
XCUR
Relative Strength Index (RSI) 56.30 30.78
Support Level $0.90 N/A
Resistance Level $1.33 $2.02
Average True Range (ATR) 0.10 0.14
MACD 0.02 0.00
Stochastic Oscillator 58.95 20.00

Price Performance

Historical Comparison
HUDI
XCUR

About HUDI Huadi International Group Co. Ltd.

Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Company generates revenue from Sales of steel piping products. Products are exported to the United States, Mexico, Thailand, Singapore, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: